|Systematic (IUPAC) name|
|Metabolism||Hydrolyzed to furoic acid and diloxanide, which undergoes extensive glucuronidation|
|Excretion||Renal (90%), fecal (10%)|
|14px (what is this?)|
Diloxanide furoate is a luminal amebicide used in the treatment of Amebiasis. It is considered the luminal agent of choice for mild intestinal amebiasis or asymptomatic cyst carriers.It can also be added to metronidazole(active drug in luminal and extraintestinal amebiasis) in acute amebic dysentery as well as hepatic abscess(In hepatic abscess it is for the control of cysts in the lumen which may cause relapse). The drug was discovered by The Boots Company Plc in 1956 and introduced as Furamide. The Furamide brand is now owned by Abbott Laboratories. It is not available in the US. In India it is available as Amicline by Franco-Indian.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
Safety and effectiveness
A 13-year study conducted by the United States Center for Disease Control between 1977 and 1990 found that this drug had a low incidence of side effects and was successful in treatment of 86% of asymptomatic carriers of Entamoeba histolytica. 
- Fernandes H, D'Souza CR, Swethadri GK, Naik CN (2009). "Ameboma of the colon with amebic liver abscess mimicking metastatic colon cancer". Indian J Pathol Microbiol 52 (2): 228–30. PMID 19332922. doi:10.4103/0377-4929.48927.
- "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
- McAuley JB, Herwaldt BL, Stokes SL et al. (1992). "Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States". Clin. Infect. Dis. 15 (3): 464–8. PMID 1520794. doi:10.1093/clind/15.3.464.
Lua error in package.lua at line 80: module 'Module:Buffer' not found.